Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was up 20.6% during trading on Thursday . The stock traded as high as $0.3256 and last traded at $0.3256. Approximately 686 shares changed hands during trading, a decline of 88% from the average daily volume of 5,944 shares. The stock had previously closed at $0.27.
Avenue Therapeutics Trading Up 20.6%
The business’s 50 day moving average price is $0.41 and its two-hundred day moving average price is $0.42. The company has a market capitalization of $1.07 million, a price-to-earnings ratio of 0.02 and a beta of -0.21.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Featured Articles
- Five stocks we like better than Avenue Therapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
